Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of Autism Spectrum Disorder.~* Have social anxiety.~* Are at least 21 years old.~* Have completed two years of college-level education or comparable vocational training.~* Are willing to refrain from psychiatric medication for at least 5 half-lives plus a week prior to experimental session.~* Agree to follow all study-related instructions and restrictions, including restrictions on food, alcohol and caffeine consumption prior to experimental sessions.~* Are willing to commit to preparatory sessions, medication management, experimental sessions, follow-up sessions and to complete evaluation instruments.~* Agree not to use MDMA/ecstasy outside of study sessions during the study, including the follow up period.~* Are willing to be contacted on a daily basis for a week after each experimental session.~* Are willing to provide a contact that is willing and able to be reached by investigators, accompany the subject during some or all of the study visits, and complete study measures.~* Are willing to give blood samples.~* Are proficient in speaking and reading English. Subjects communicating with text-to-speech technology will also be permitted to enroll.~Exclusion Criteria:~* Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.~* Are abusing illegal drugs.~* Are not able to give adequate informed consent.~* Are not able to attend face-to-face visits or those who plan to move out of the area within the treatment period.~* Are pregnant or nursing, or if are able to bear children and do not practice an effective means of birth control.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inactive Placebo with Therapy (Type: PLACEBO_COMPARATOR): Participants will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
- Group 1: MDMA-assisted therapy 75 mg/100mg (Type: EXPERIMENTAL): Participants will receive 75 mg and 100 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.
- Group 2: MDMA-assisted therapy 100 mg/125 mg (Type: EXPERIMENTAL): Participants will receive 100 mg and 125 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).